‘Disappointing results’ for Novartis & MorphoSys phase III in Muscle Disease

27/04/2016 - 2 minutes

MorphoSys confirms that its antibody (bimagrumab) failed to meet the primary endpoint of a phase IIb/III trial for a muscle disease (sIBM), conducted by Novartis.

morphosys_novartis_phase_III_bimagrumabSad news for Novartis and MorphoSys. The two companies are developing bimagrumab for muscle diseases, as part of their ongoing collaboration, which has already resulted in 11 programmes.

Bimagrumab was initially created by MorphoSys, a product of its HuCAL antibody library. It was then licensed to Novartis, which started this phase II/III trial in October 2013 – shortly after receiving FDA Breakthrough Therapy.

The trial enrolled 240 patients with sporadic inclusion body myositis (sIBM), a rare debilitating muscle disease still without an approved treatment.

Recently, Novartis announced that this trial did not meet its primary endpoint – increasing the walking distance of patients in a given timeframe.

The trial is still ongoing, while the data is reviewed to make a decision on the programme –

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!